AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00632554
Drug: prednisolone 0.5 mg/kg/day for three months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: period of treatment
Trial: NCT00632554
Drug: prednisolone 0.5 mg/kg/day for six months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: period of therapy
Trial: NCT00565279
Drug: ASF1057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, topical
Trial: NCT00565279
Drug: ASF1057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, Topical
Trial: NCT00409383
Drug: Genasense® (oblimersen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
Trial: NCT00409383
Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
Trial: NCT00409383
Drug: Temodar® (temozolomide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
Trial: NCT04683185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6742-matched placebo tablets.
Trial: NCT03718611
Drug: BR9001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR9001 is a test drug as generic
Trial: NCT03718611
Drug: BR900A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR900A is a reference drug
Trial: NCT02109328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets
Trial: NCT04010942
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT00738972
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin. Duration: 12 months. Tablets
Trial: NCT00738972
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin. Duration: 12 months. Tablets
Trial: NCT00738972
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Trial: NCT01281748
Drug: intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
Trial: NCT00006125
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00838565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion on three consecutive months
Trial: NCT01974193
Drug: Floseal
RxNorm normalized name: Floseal Hemostatic Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of floseal on intervention arm
Trial: NCT02815228
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
Trial: NCT01822132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01172652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control
Trial: NCT03794037
Drug: dydrgesterone 10 mg( tab)/12hs/14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
Trial: NCT03748199
Drug: POL6014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)
Trial: NCT03748199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally at a dose and frequency matched to POL6014
Trial: NCT00882258
Drug: 12.5 mg Proellex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg Proellex administered orally daily
Trial: NCT00882258
Drug: 25 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Proellex administered orally daily
Trial: NCT00882258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily
Trial: NCT03152370
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT00218517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules using blue 00 capsules
Trial: NCT03207243
Drug: GSK3772847
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
Trial: NCT03533387
Drug: MN-166
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Trial: NCT02803918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT01800617
Drug: Liothyronine, Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02702401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.90% w/v sodium chloride IV infusion
Trial: NCT02608112
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
Trial: NCT03207243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
Trial: NCT00677807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Trial: NCT01336686
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for 4 weeks
Trial: NCT01686646
Drug: paracetamol + caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paracetamol with caffeine
Trial: NCT00501202
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 4 weeks
Trial: NCT04019041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 mL pre-filled syringe
Trial: NCT02776228
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
Trial: NCT01388842
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Trial: NCT01388842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Trial: NCT00991419
Drug: [18F]AZD4694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
Trial: NCT01032135
Drug: medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for naltrexone
Trial: NCT02362165
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/d,once-weekly,per oral.
Trial: NCT02362165
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9mg/㎡,d1-4
Trial: NCT01693328
Drug: PecFent® (fentanyl) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03126097
Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
Trial: NCT03126097
Drug: COCP Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
Trial: NCT00945503
Drug: GSK1018921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1018921 is a GT1 recepor antagonist
Trial: NCT02411331
Drug: Ethanol 40% + Enoxaparine 400UI/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03087201
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: analogous to experimental intervention
Trial: NCT00699972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Trial: NCT04623164
Drug: Cocktail from complex phytoadaptogens (CFA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
Trial: NCT02188368
Drug: POM
RxNorm normalized name: Ipomea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188368
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188368
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188368
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02710604
Drug: CMX157
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02487108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
Trial: NCT02978287
Drug: BAVU Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue preservation solution for transplantation
Trial: NCT02881996
Drug: IV tylenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tylenol given scheduled in addition to standard PCA
Trial: NCT02881996
Drug: No IV tylenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional IV Tylenol given
Trial: NCT02881996
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: both groups receive as part of our standard postop pain protocol after all operations
Trial: NCT03611569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - concentrate for solution for infusion, single dose
Trial: NCT00419562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule designed to match active drug
Trial: NCT01095588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets
Trial: NCT02250209
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles.
Trial: NCT02244203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01127503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules were identically matched to Metyrosine.
Trial: NCT01921829
Drug: Protocolized Diuretic Strategy
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide).
Trial: NCT01715818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching aleglitazar placebo tablet orally daily
Trial: NCT01024543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03646721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
Trial: NCT01466270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00839293
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once, see arm description for more information
Trial: NCT02361528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneously, for 5 days
Trial: NCT02365636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
Trial: NCT06161792
Drug: 0.8 mg RCN3028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06161792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02866838
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT01697657
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Trial: NCT00826267
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
Trial: NCT02623803
Drug: Placebo D5W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04066426
Drug: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
Trial: NCT02559388
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
Trial: NCT00395239
Drug: inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Trial: NCT01604343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
Trial: NCT01604343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
Trial: NCT04264286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will prophylactic placebo after the end of the surgery
Trial: NCT00820612
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PR once at the time of ERCP
Trial: NCT00436748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
Trial: NCT00661700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
Trial: NCT00215046
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
Trial: NCT01217918
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg or placebo a material sparing tablet per day for 10 days
Trial: NCT01217918
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg or placebo as a material sparing tablet per day for 10 days
Trial: NCT00414661
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Trial: NCT00357370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, up to 12 weeks
Trial: NCT03636750
Drug: HB002.1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
Trial: NCT03096522
Drug: Phenytoin 2% spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
Trial: NCT00783042
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
Trial: NCT00783042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, once daily for 1 month (double blind)
Trial: NCT01202825
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
Trial: NCT01202825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
Trial: NCT01202825
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
Trial: NCT01202825
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
Trial: NCT01202825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII